Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature

Table 3

Clinical trials of 177Lu-DOTATATE and 90Y-DOTATOC in advanced NETs.

Treatment regimen	Patients (number)	ORR (%)	Median PFS (months)	Criteria	Reference
Phase III studies
NETTER-1 study
177Lu-DOTATATE	116		Not achieved	RECIST	[83]
Octreotide LAR	113		8.4
Phase I and II studies
177Lu-DOTATATE	310	29	33	RECIST	[80]
177Lu-DOTATATE	26	38		RECIST	[84]
177Lu-DOTATATE	12	17		RECIST	[85]
177Lu-DOTATATE	42	32	36	RECIST	[86]
90Y-DOTATOC	58	23	17	RECIST	[87]
90Y-DOTATOC	53	23	29	RECIST	[88]
90Y-DOTATOC	90	4	16	RECIST	[89]
90Y-DOTATOC	58	9	29	RECIST	[90]
90Y-DOTATOC	21	29		RECIST	[91]

ORR, overall response rate; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; LAR, long-acting release.